Literature DB >> 7517275

Experience with buccal phentolamine mesylate for impotence.

A W Zorgniotti1.   

Abstract

Satisfactory erection with penetration can be obtained in impotent men by the oral or buccal administration of the alpha-adrenergic antagonist, phentolamine. This agent is also used in conjunction with papaverine HCl for intracavernous injection. The previous observation by Gwinup, that 50 mg of phentolamine HCl po, 1.5 hours before coitus resulted in erection in 11/16 patients, is confirmed. This study, using phenoxybenzamine as the placebo, was repeated with success in 36/85 (42.3%) patients. Because of cost and to decrease the waiting time, a buccal form of phentolamine mesylate was administered (20 mg) with erection and penetration in 21/69 (31.8%). There was no correlation between the degree of penile vascular insufficiency or age and the effectiveness of phentolamine. Buccal phentolamine is shown to increase flow velocity in the dorsal penile artery. Phentolamine produces minimal side effects, including hypertension in the subjects.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7517275

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  8 in total

1.  Erectile dysfunction: diagnosis and management with newer oral agents.

Authors:  C C Carson
Journal:  Proc (Bayl Univ Med Cent)       Date:  2000-10

Review 2.  The Management of Unplanned Erection during Endoscopic Urological Surgery.

Authors:  Martin Gray; Nikhil Vasdev; Shan Gowrie-Mohan; Tom McNicholas
Journal:  Curr Urol       Date:  2017-07-30

Review 3.  Aetiology and management of male erectile dysfunction and female sexual dysfunction in patients with cardiovascular disease.

Authors:  Stephen L Archer; Ferrante S Gragasin; Linda Webster; Derek Bochinski; Evangelos D Michelakis
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 4.  Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications.

Authors:  Hao Zhang; Jie Zhang; James B Streisand
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 5.  Pharmacological management of erectile dysfunction.

Authors:  F Montorsi; G Guazzoni; P Rigatti; G Pozza
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

Review 6.  Treatment of erectile dysfunction in patients with cardiovascular disease : guide to drug selection.

Authors:  Graham Jackson
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 7.  A risk-benefit assessment of sildenafil in the treatment of erectile dysfunction.

Authors:  D Vitezic
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

8.  Oral phentolamine mesylate in the treatment of complex regional pain syndrome.

Authors:  G J McCleane
Journal:  Ulster Med J       Date:  1996-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.